teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 62
teleo-codex/entities/health/maps-pbc.md
Teleo Agents 42d0c1c2bd
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
Details
vida: extract claims from 2024-08-09-fda-mdma-ptsd-complete-response-letter-lykos 
- Source: inbox/queue/2024-08-09-fda-mdma-ptsd-complete-response-letter-lykos.md
- Domain: health
- Claims: 2, Entities: 2
- Enrichments: 0
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
2026-05-10 04:28:36 +00:00

1 KiB
Raw Blame History

MAPS Public Benefit Corporation

Type: Nonprofit public benefit corporation Parent: Multidisciplinary Association for Psychedelic Studies (MAPS) Focus: Psychedelic-assisted therapy development Status: Separated from Lykos Therapeutics operations (2024)

Overview

MAPS Public Benefit Corporation was the nonprofit pharmaceutical development arm of MAPS (Multidisciplinary Association for Psychedelic Studies), a 40+ year organization pioneering psychedelic therapy research. MAPS PBC created Lykos Therapeutics to advance MDMA-assisted therapy through FDA approval.

Organizational Structure

MAPS PBC operated as the parent organization to Lykos Therapeutics, maintaining nonprofit status while conducting pharmaceutical development. Following the FDA Complete Response Letter in August 2024, MAPS PBC and Lykos separated operations.

Timeline

  • 2024-08 — Separated operations from Lykos Therapeutics following FDA Complete Response Letter

Sources

  • Psychiatric Times, September 2025
  • STAT News, October 2025